-
Je něco špatně v tomto záznamu ?
Estrogeny a kostní nemoc u chronického onemocnění ledvin - úloha FGF23
[Estrogens and bone disease in chronic kidney disease: role of FGF23]
Jorge B. Cannata-Andía, Natalia Carrillo-López, Manuel Naves-Díaz
Jazyk čeština Země Česko
Typ dokumentu přehledy
- MeSH
- chronické selhání ledvin komplikace metabolismus MeSH
- estrogeny farmakologie fyziologie metabolismus MeSH
- fibroblastové růstové faktory metabolismus MeSH
- financování organizované MeSH
- kosti a kostní tkáň metabolismus účinky léků MeSH
- lidé MeSH
- nemoci kostí etiologie metabolismus MeSH
- parathormon fyziologie MeSH
- signální transdukce MeSH
- vitamin D fyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- přehledy MeSH
PURPOSE OF REVIEW: To describe the direct and indirect effects of estrogen on bone with special emphasis on the analysis of the recent findings related to the putative role of FGF23 in the estrogen-dependent parathyroid hormone (PTH) suppression. RECENT FINDINGS: Estrogens act directly on bone cells, downregulating osteoclast precursors and differentiation, increasing osteoclast apoptosis and stimulating osteoblast proliferation and differentiation. However, estrogens can also act indirectly on bone, modulating the calcium-phosphorus-vitamin D-PTH axis. It has been recently demonstrated that estrogens suppress PTH synthesis and secretion in a dose-dependent manner and reduce serum calcitriol and phosphorus levels by an indirect mechanism. In-vivo and in-vitro experiments demonstrated that FGF23 positively correlated, also in a dose-dependent manner, with the dose of estrogens and with the observed changes in calcitriol and phosphorus. SUMMARY: These new findings support the importance of the indirect effects of estrogens on bone, suggesting a role for FGF23 in the regulation of PTH by estrogens.
Estrogens and bone disease in chronic kidney disease: role of FGF23
Lit.: 52
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10036012
- 003
- CZ-PrNML
- 005
- 20111210200748.0
- 008
- 110107s2010 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Cannata-Andía, Jorge B.
- 245 10
- $a Estrogeny a kostní nemoc u chronického onemocnění ledvin - úloha FGF23 / $c Jorge B. Cannata-Andía, Natalia Carrillo-López, Manuel Naves-Díaz
- 246 11
- $a Estrogens and bone disease in chronic kidney disease: role of FGF23
- 314 __
- $a Bone and Mineral Research Unit, Hospital Universitario Central de Asturias, Instituto Reina Sofía de Investigación, REDinREN del ISCIII, Universidad de Oviedo, Oviedo, Asturias, Spain metoseo@hca.es
- 504 __
- $a Lit.: 52
- 520 9_
- $a PURPOSE OF REVIEW: To describe the direct and indirect effects of estrogen on bone with special emphasis on the analysis of the recent findings related to the putative role of FGF23 in the estrogen-dependent parathyroid hormone (PTH) suppression. RECENT FINDINGS: Estrogens act directly on bone cells, downregulating osteoclast precursors and differentiation, increasing osteoclast apoptosis and stimulating osteoblast proliferation and differentiation. However, estrogens can also act indirectly on bone, modulating the calcium-phosphorus-vitamin D-PTH axis. It has been recently demonstrated that estrogens suppress PTH synthesis and secretion in a dose-dependent manner and reduce serum calcitriol and phosphorus levels by an indirect mechanism. In-vivo and in-vitro experiments demonstrated that FGF23 positively correlated, also in a dose-dependent manner, with the dose of estrogens and with the observed changes in calcitriol and phosphorus. SUMMARY: These new findings support the importance of the indirect effects of estrogens on bone, suggesting a role for FGF23 in the regulation of PTH by estrogens.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nemoci kostí $x etiologie $x metabolismus $7 D001847
- 650 _2
- $a kosti a kostní tkáň $x metabolismus $x účinky léků $7 D001842
- 650 _2
- $a estrogeny $x farmakologie $x fyziologie $x metabolismus $7 D004967
- 650 _2
- $a fibroblastové růstové faktory $x metabolismus $7 D005346
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronické selhání ledvin $x komplikace $x metabolismus $7 D007676
- 650 _2
- $a parathormon $x fyziologie $7 D010281
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a vitamin D $x fyziologie $7 D014807
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Carrillo-López, Natalia
- 700 1_
- $a Naves-Díaz, Manuel
- 773 0_
- $w MED00156014 $t Current opinion in nephrology and hypertension $g Roč. 4, č. 3 (2010), s. 62-66 $x 1802-3827
- 910 __
- $a ABA008 $b B 2490 $c 903 $y 7
- 990 __
- $a 20110106080203 $b ABA008
- 991 __
- $a 20110107100240 $b ABA008
- 999 __
- $a ok $b bmc $g 824755 $s 689919
- BAS __
- $a 3
- BMC __
- $a 2010 $b 4 $c 3 $d 62-66 $m Current Opinion in Nephrology and Hypertension (České vyd.) $x MED00156014
- LZP __
- $a 2011-01/mkme